|
Daily Medical Update
Atopic dermatitis
Saturday, April 18, 2026
|
🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the
last 12 months.
|
Journal of the American Academy of Dermatology (2025) - Practice Guideline
Key Findings
- The update increased the number of strongly recommended FDA-approved options for adult AD by adding tapinarof cream, roflumilast cream, lebrikizumab, and nemolizumab.
- Most supporting trials improved short-term disease outcomes, but short follow-up reduces certainty about long-term comparative safety and efficacy.
📋 Practice Implication: Adult treatment algorithms should now explicitly incorporate these four newer agents when standard topical regimens or earlier biologic strategies are no longer sufficient.
|
The Journal of dermatological treatment (2026) - Network Meta-Analysis
Key Findings
- Across 33 trials and 16,334 participants, upadacitinib 30 mg improved the likelihood of EASI-75, EASI-90, IGA 0/1, and itch NRS response more than other targeted therapies.
- No significant efficacy differences were seen for dupilumab 300 mg vs stapokibart 300 mg or ivarmacitinib 8 mg vs upadacitinib 15 mg on indirect comparison.
📋 Practice Implication: When escalating refractory moderate-to-severe disease, clinicians can frame upadacitinib 30 mg as the current efficacy benchmark while recognizing that some newer agents appear comparable on indirect evidence.
|
BMC medicine (2026) - Network Meta-Analysis
Key Findings
- Dupilumab 300 mg reduced asthma risk vs nemolizumab 90 mg (RR 0.10, 95% CI 0.01-0.93), and tralokinumab 150 mg also reduced asthma risk (RR 0.03, 95% CI 0-0.77).
- For allergic rhinitis, dupilumab 200 mg reduced ranked risk the most, whereas abrocitinib 100 mg increased ranked risk the most in SUCRA analyses.
📋 Practice Implication: In patients whose eczema coexists with airway atopy, dupilumab or tralokinumab may be easier to favor than abrocitinib when respiratory comorbidity risk is part of the treatment decision.
|
American journal of clinical dermatology (2025) - Systematic Review
Key Findings
- At 16 weeks, pooled EASI-75/EASI-90 rates were 75%/38% for abrocitinib, 51%/24% for baricitinib, and 83%/55% for upadacitinib in real-world practice.
- Real-world response rates improved over time and remained comparable to trial benchmarks, although acne and herpes simplex were frequent adverse events across JAK inhibitors.
📋 Practice Implication: Shared decisions about oral JAK inhibitors should pair strong expected skin clearance with explicit counseling on acne, herpes simplex, and routine safety monitoring.
|
Pediatric allergy and immunology (2025) - Systematic Review
Key Findings
- Across 9 studies with 2,182 children, topical targeted therapies improved EASI scores by a mean -56.67% (95% CI -59.16% to -54.18%).
- Treatment-emergent adverse events did not increase vs control (risk difference 0.00, 95% CI -0.02 to 0.02).
📋 Practice Implication: For children needing steroid-sparing escalation, topical JAK and PDE4 agents look reasonable before systemic therapy, especially when short-term safety is the main barrier.
|
|
💡
Summary
Recent atopic dermatitis literature is dominated by therapeutic evidence: the adult AAD focused update adds tapinarof, roflumilast, lebrikizumab, and nemolizumab, while indirect and real-world syntheses continue to place upadacitinib and other JAK inhibitors among the most effective options for moderate-to-severe disease. The newer data also sharpen treatment selection, showing lower airway-comorbidity risk rankings with dupilumab and tralokinumab, persistent monitoring needs for acne and herpes simplex with oral JAK inhibitors, and meaningful short-term steroid-sparing benefit from targeted topical therapies in children.
|
|